Clinical Trial

Genetic Testing and Motivational Counseling for FH

Study acronym: GENMOTIV-FH
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2024 (before its estimated January 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To date, there are highly effective lipid-lowering drugs, the combination of which makes it possible to achieve the target level of LDL-C in most patients with familial hypercholesterolemia (FH). However, the effectiveness of treatment of FH patients strongly depends on adherence to lipid-lowering therapy and to the healthy lifestyle, as well as the detection of the disease and the therapy prescription as early as possible, better in childhood. The aim of the study is to assess the impact of genetic testing and motivational counseling on the effectiveness of treatment and cascade screening in patients with FH.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-11-30; most recent amendment 2024-12-16.
Status change: Recruiting → Active, Not Recruiting 2024-12-16
Trial Details
NCT Number NCT04656028
Lead Sponsor National Medical Research Center for Therapy and Preventive Medicine
Collaborators: Moscow State University of Medicine and Dentistry
Conditions Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2, Hypercholesterolemia, Familial, 3, Hypercholesterolemia, Familial, 4, Hypercholesterolemia, Familial, 4, Autosomal Recessive, Familial Hypercholesterolemia With Hyperlipemia, Hypercholesterolemia, Autosomal Dominant, Type B +18 more
Enrollment 180 participants
Start Date 2020-06-15
Primary Completion 2025-01-30 (estimated)
Study Completion 2025-03-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-17